Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to \< 18 years of age with recent...
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD)....
Top Cities for Neuromyelitis Optica Clinical Trials
Neuromyelitis Optica clinical trials are recruiting across 16 cities. Here are the cities with the most active studies:
About Neuromyelitis Optica
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease that primarily attacks the optic nerves and spinal cord, causing vision loss and paralysis. It is distinct from multiple sclerosis and often involves aquaporin-4 antibodies. Treatment includes immunosuppressive therapies and biologics.
Clinical trials are advancing new treatments for neuromyelitis optica. Currently, 2 studies are recruiting a combined 27 participants across the United States. Research is being conducted by 2 organizations including Amgen, Alexion Pharmaceuticals, Inc..
2026 Neuromyelitis Optica Research Landscape
As of March 2026, the neuromyelitis optica clinical trial landscape includes 2 actively recruiting studies across 16 cities in the United States. These studies are collectively seeking 27 participants, with an average enrollment target of 14 per study.
Research is being led by 2 different organizations, including Amgen, Alexion Pharmaceuticals, Inc..
Geographically, neuromyelitis optica trials are most concentrated in Boston, Massachusetts (2 trials); São Paulo, (2 trials); Toronto, Ontario (2 trials); Le Kremlin, Bicêtre-Val-de-Marne (2 trials); La Jolla, California (1 trial) and 7 other cities.
Featured Neuromyelitis Optica Studies
Highlighted recruiting studies for neuromyelitis optica, selected by enrollment size and research scope.
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to \< 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin \[Ig\]G).
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).
Frequently Asked Questions About Neuromyelitis Optica Clinical Trials
Are there neuromyelitis optica clinical trials near me?
Yes, there are 2 neuromyelitis optica clinical trials currently recruiting across 16+ cities in the United States, including Boston, Massachusetts; São Paulo, ; Toronto, Ontario. Browse the studies above to find one at a location convenient for you.
How do I join a neuromyelitis optica clinical trial?
To join a neuromyelitis optica clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are neuromyelitis optica clinical trials free?
Yes, participation in neuromyelitis optica clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of neuromyelitis optica treatments are being studied?
Current neuromyelitis optica clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 2 research organizations.
Is it safe to participate in neuromyelitis optica clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov